Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $151,362.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 2,803 shares of the firm’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $54.00, for a total transaction of $151,362.00. Following the completion of the transaction, the insider now directly owns 92,231 shares in the company, valued at approximately $4,980,474. The trade was a 2.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $39.30, for a total value of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The stock was sold at an average price of $37.91, for a total value of $343,957.43.
• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.76, for a total value of $447,600.00.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock opened at $55.62 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The business’s 50 day simple moving average is $43.96 and its two-hundred day simple moving average is $40.30. The stock has a market capitalization of $4.43 billion, a P/E ratio of -14.83 and a beta of -0.16. Akero Therapeutics, Inc. has a one year low of $21.02 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $1.91. Analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AKRO. Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, May 27th. HC Wainwright lifted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Citigroup dropped their price objective on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently made changes to their positions in the company. RTW Investments LP boosted its position in shares of Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock valued at $190,840,000 after purchasing an additional 940,388 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Akero Therapeutics by 11.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company’s stock worth $194,997,000 after purchasing an additional 495,119 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Akero Therapeutics by 14.2% in the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company’s stock worth $171,256,000 after purchasing an additional 526,233 shares during the last quarter. Deep Track Capital LP raised its stake in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Akero Therapeutics by 93.3% during the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company’s stock valued at $46,786,000 after acquiring an additional 557,794 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.